Treatment of idiopathic intracranial hypertension: Topiramate vs acetazolamide, an open-label study

Acta Neurologica Scandinavica

Volumn 116, Issue 5, 2007, Pages 322-327

  Celebisoy N ^a   Gokcay F ^a   Sirin H ^a   Akyurekli O ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Acetazolamide; Idiopathic intracranial hypertension; Topiramate

Indexed keywords

ACETAZOLAMIDE; TOPIRAMATE;

ABDUCENS NERVE PARALYSIS; ADOLESCENT; ADULT; ARTICLE; BRAIN DAMAGE; CEREBROSPINAL FLUID PRESSURE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIPLOPIA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; EYE EXAMINATION; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; INTRACRANIAL HYPERTENSION; INTRACRANIAL NOISE; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING; TREATMENT RESPONSE; VISUAL FIELD; WEIGHT REDUCTION;

ACETAZOLAMIDE; ADOLESCENT; ADULT; ANTICONVULSANTS; BODY WEIGHT; CARBONIC ANHYDRASE INHIBITORS; CEREBROSPINAL FLUID PRESSURE; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOTUMOR CEREBRI; TREATMENT OUTCOME; VISION DISORDERS; VISUAL FIELDS; WEIGHT LOSS;

EID: 35148893171     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00905.x     Document Type: Article

References (24)

1. Dandy W. Intracranial pressure without brain tumor. Ann Surg 1937 106:492 513.
2. International Headache Society. The international classification of headache disorders, 2nd edn. Cephalalgia 2004 24 (Suppl. 1 9 160.
3. Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol 1988 45:875 7.
4. Radhakrishnan K, Thacker AK, Bohlaga NH et al. Epidemiology of idiopathic intracranial hypertension: a prospective and case control study. J Neurol Sci 1993 116:18 28.
5. Kesler A, Gadoth N. Epidemiology of idiopathic intracranial hypertension in Israel. J Neuroophthalmol 2001 21:12 4.
6. Kesler A, Fattal-Valevski A. Idiopathic intracranial hypertension in the pediatric population. J Child Neurol 2002 17:745 8.
7. Wall M, George D. Idiopathic intracranial hypertension: a prospective study of 50 patients. Brain 1991 114:155 80.
8. Wall M, White WN. Asymmetric papilledema in idiopathic intracranial hypertension: prospective interocular comparison of sensory visual function. Invest Ophthalmol Vis Sci 1998 39:134 42.
9. Rowe RJ, Sarkies NJ. Assessment of visual function in idiopathic intracranial hypertension: a prospective study. Eye 1998 10:221 9.
10. Skau M, Brennum J, Gjerris F, Jensen R. What is new about idiopathic intracranial hypertension? An updated review of mechanism and treatment. Cephalalgia 2005 26:384 99.
11. Ball AK, Clarke CE. Idiopathic intracranial hypertension. Lancet Neurol 2006 5:433 42.
12. Friedman DI. Cerebral venous pressure, intra-abdominal pressure, and dural venous stenting in idiopathic intracranial hypertension. J Neuroophthalmol 2006 26:61 4.
13. Goodwin J. Recent developments in idiopathic intracranial hypertension. Semin Ophthalmol 2003 18:181 9.
14. Pagan FL, Restrepo L, Balish M et al. A new drug for an old condition. Headache 2002 42:695 6.
15. Palacio E, Rodero L, Pascual J. Topiramate-responsive headache due to idiopathic intracranial hypertension in Behçet syndrome. Headache 2004 44:436 7.
16. Frisen L. Swelling of the optic nerve head: a staging scheme. J Neurol Neurosurg Psychiatry 1982 45:13 8.
17. Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005 3:CD003434.
18. Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic and clinical data. Clin Ther 1997 19:1294 308.
19. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000 41 (Suppl 1 35 9.
20. Ben-Menachem E, Axelsen M, Hellebö Johanson E et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003 11:556 62.
21. Bray GA, Hollander P, Klein S et al. for the US Topiramate Research Group. A 6-month randomized, placebo controlled dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003 11:722 33.
22. Boentert M, Aretz H, Ludemann P. Acute myopia and angle-closure glaucoma induced by topiramate. Neurology 2003 61:1306.
23. Chen TC, Chao CW, Sorkin JA. Topiramate induced myopic shift and angle-closure glaucoma. Br J Ophthalmol 2003 87:648 9.
24. Çelebisoy N, Seçil Y, Akyürekli O. Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey. Acta Neurol Scand 2002 106:367 70.